AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

and eye care, its entry into neuroscience provides new growth opportunities and diversifies its revenue streams. For investors, the emphasis should be on AbbVie’s strong pipeline in these ...

AbbVie: Sales of AbbVie’s blockbuster drug ... This led the shares of the company to drop after third-quarter results following a powerful first-half performance. Nonetheless, the company ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Price and Consensus: PFE AbbVie: Sales of AbbVie’s blockbuster ... This led the shares of the company to drop after third-quarter results following a powerful first-half performance.

Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...